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INTrOducTION
Progress towards the reduction in child mortality target in 
Millennium Development Goal (MDG) 4 is being made in 
many low- and middle-income countries (1). This is main-
ly as a result of notable efforts of national governments and 
the international community to improve the prevention 
and treatment of the main causes of child death and to ex-
pand access to health care. The exact causes of the sharp 
declines in child mortality have not been identified defini-
tively but successful countries have significantly increased 
coverage of basic public health interventions and increased 
The global health agenda beyond 2015 will inevitably need to broaden its focus from mortality re-
duction to the social determinants of deaths, growing inequities among children and mothers, and 
ensuring the sustainability of the progress made against the infectious diseases. New research tools, 
including technologies that enable high-throughput genetic and ‘-omics’ research, could be deployed 
for better understanding of the aetiology of maternal and child health problems. The research need-
ed to address those challenges will require conceptually different studies than those used in the past. 
It should be guided by stringent ethical frameworks related to the emerging collections of biological 
specimens and other health related information. We will aim to establish an international birth co-
hort which should assist low- and middle-income countries to use emerging genomic research tech-
nologies to address the main problems in maternal and child health, which are still major contribu-
tors to the burden of disease globally.
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access to quality health services (1). The ‘advanced market 
commitment’ programmes, which are heavily supported 
by The Gates Foundation, Global Alliance for Vaccines and 
Immunization and national governments of the developed 
countries, will try to sustain and enhance the development 
and implementation of vaccination against major patho-
gens throughout the developing world (2).
Many low- and middle-income countries are now experi-
encing a markedly different pattern of early mortality, with 
more than half of child 
deaths attributable to causes 
directly related to birth and 
very early infections and 
complications – such as pre-
term birth complications, 
birth asphyxia, congenital 
anomalies, sudden infant 
death syndrome and acci-
dents (3). At the same time, 
attention is shifting from not 
only ensuring survival, but 
also attaining optimal development. A growing body of 
evidence suggests that social and environmental influences, 
especially during pregnancy and in early childhood, can 
have important long term health and development impli-
cations (4). Another important trend that accompanies the 
epidemiological and demographic transitions is increasing 
inequities in child health outcomes within countries.
The global child health agenda for 2015 and beyond will 
inevitably need to broaden its focus from mortality reduc-
tion to also addressing the social determinants of deaths, 
growing inequities among children and mothers, and en-
suring the sustainability of the progress made against the 
infectious diseases. With continued reduction in child mor-
tality, the focus of international efforts will also need to shift 
from merely averting deaths to promoting better health, 
development, social functioning and education of children 
in the poorest countries and reduce the effects of inequity. 
The research needed to address those challenges will re-
quire conceptually different studies than those used in the 
past to address infectious causes.
HumaN gENOmE PrOjEcT  
aNd mEdIcal rESEarcH
The past decade has witnessed remarkable progress in the 
development of more reliable, replicable and standardized 
methods that have improved the quality of research in all 
areas of human health and development. This is true 
across a wide range of disciplines, from qualitative re-
search and indicators of quality of life or inequity, to cut-
ting-edge basic research. In parallel to global child mor-
tality reduction, we have witnessed a particular revolution 
in biomedical research which was brought about by the 
progress in genetic technology as a result of the Human 
Genome Project (5).
Genome-wide association studies and whole-genome se-
quencing have led to an unprecedented level of discovery 
with novel insights into human biology and the genetic 
determinants of many common and rare human diseases. 
However, common human diseases of late onset – such 
as cardiovascular diseases, 
most types of cancer, or 
type 2 diabetes, which are 
typical of the industrialized 
countries, have a complex 
aetiology, including large 
numbers of strong environ-
mental, social and behav-
ioural determinants and 
non-genetic risk factors. 
For most traits studied, the 
contribution of genetic fac-
tors associated with those diseases is due to many com-
mon genetic variants, each with very small effects (6). 
More importantly, the research into genetic determinants 
of common human diseases has been very largely con-
fined to industrialized countries and focused on their 
health needs, which form a relatively minor part of the 
global burden of disease (6). Several researchers in the 
field have expressed concern that genetic research into 
common diseases of late onset conducted to date has 
mainly been serving to increase the gap between the 
health needs of the global poor and the rich (7). 
In the past 2 million years of human evolution, diseases of 
the late onset had little impact on the natural selection pro-
cesses that shaped the human genome. They occur in a 
post-reproductive period and are therefore almost invisible 
to selection. Thus their genetic architecture is likely to be 
mostly defined by so-called ‘neutral evolution’. Diseases 
and conditions that had a much greater power to shape hu-
man genetic make-up – the problems related to birth, ear-
ly child survival and maternal mortality – are still present 
in low-income countries. Those are mainly the problems 
occurring during labour and persisting infectious causes of 
mortality of children and young people. They have been 
shaping the human genome through natural selection. Ap-
plying new genetic technologies to study the genetic vari-
ants protecting from the major causes of maternal and child 
deaths would likely yield significant insights into patho-
genesis of those diseases and mechanisms of evolved host 
resistance. Moreover, some of these traits are likely to be 
subject to balancing and shifting selection, and may reveal 
larger genetic effects.
The progress made recently through the ap-
plication of novel genetic technologies in 
large population cohorts has also exposed 
the importance of very large and well-de-
signed studies with adequate power to test 
study hypotheses. large multi-centre stud-
ies using rigorous statistical approach lead 
to reproducible and consistent findings.
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Another impact of the human genome project was the de-
velopment of technologies for fast and relatively cheap 
sequencing of genomes. Currently, a polymerase chain 
reaction (PCR) test for a specific infectious agent can be 
developed in the course of few days through re-sequenc-
ing of the genome of an infectious agent, as demonstrated 
by a recent example during the H1N1 (‘swine’) flu out-
break in 2009.
largE-ScalE bIOmEdIcal ScIENcE 
The progress made recently through the application of nov-
el genetic technologies in large population cohorts has also 
exposed the importance of very large and well-designed 
studies with adequate power to test study hypotheses. Com-
parison of small candidate gene studies (which were rou-
tinely performed in 1990s and in the beginning of 2000s) 
with large multi-centre collaborative genome-wide associa-
tion studies (which became very popular from about 2007) 
shows that conducting many small studies with insufficient 
power and without the standardized methodology is an in-
efficient use of resources and leads to inconsistent and false 
positive reports in an overwhelming majority of cases. Con-
versely, large multi-centre studies using rigorous statistical 
approach lead to reproducible and consistent results. 
The need for large scale collaborative research programmes 
is even more important as research turns to the study of 
the interaction of genes and environment in causing disease 
(8). This problem is not limited to genetic research. Infor-
mation on morbidity and mortality from the diseases of the 
poor, which form the large majority of global burden of 
disease and death, is often based on data from relatively 
few studies conducted in different low-income contexts 
without standardized methods. They often provide very 
inconsistent estimates that are not comparable. The recent 
progress made by genome-wide association studies and, 
more generally, in the field of genetic epidemiology, has 
highlighted the importance of ‘biobanks’. These are large 
collections of biological material and extensive associated 
epidemiological data from large population cohorts assem-
bled in a standardized way. They are designed and devel-
oped with close attention to quality assurance, so that 
emerging technologies can be applied to generate high 
quality reproducible data on very large numbers of well 
characterised individuals. One of the main reasons why the 
developing world is not enjoying potential benefits from 
the application of novel epidemiological and genetic re-
search technologies is because there are very few biobanks 
and large population cohort studies in low- and middle-
income countries available for systematic study (see Camp-
bell et al. (9) and McKinnon et al. (10) in this issue). Such 
cohorts are becoming a pre-requisite for reliable research 
into biological, environmental, genetic, behavioural and 
social determinants of diseases relevant to their population.
THE caSE fOr lauNcH Of aN 
INTErNaTIONal dNa-baSEd bIrTH 
cOHOrT STudy
The development of a very large dataset (‘biobank’) that 
would include or contain directly comparable data on ep-
idemiological, biological and social factors and samples 
representative of a large number of human populations 
would allow researchers to study the determinants of dis-
eases which have made major contributions to the global 
burden of disease, thus reducing the large inequity in re-
search effort on different causes of morbidity and mortal-
ity globally. An international biobank would allow re-
searchers in low- and middle-income countries to gain 
access to emerging research technologies and use them to 
study diseases that affect their populations. It would also 
serve to build and enhance the research capacity in devel-
oping countries, to create a large collaborating network of 
interested researchers globally, and to enable comparisons 
between their results using the same methodology. The re-
sults of biomedical research that would be generated from 
such a biobank would make a substantial contribution to 
improving the available information on the morbidity, mor-
tality and the main risk factors for the diseases relevant to 
the developing world and provide the opportunity to study 
interactions between genes and a wide range of levels of 
environmental exposures in causing diseases in different 
contexts (8). The longitudinal nature of the study could 
provide valuable information on long-term (life-course) ef-
fects of biological, environmental, genetic, social and other 
factors and their interplay in the modern age.
The development of a global birth cohort would hold out 
the promise of understanding genetic, environmental and 
social determinants of health, development and survival of 
pre-school children. It would also enhance our understand-
ing of the interactions of context-specific social, economic 
and environmental factors and the human genetic make-
up. Ultimately, what will start as a cohort of newborns and 
children will eventually, over the course of the 21st century, 
One of the main reasons why low and mid-
dle income countries are not enjoying po-
tential benefits from the application of nov-
el epidemiological and genetic research 
technologies is because there are very few 
biobanks and large population cohort stud-
ies available for systematic study.
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develop into a longitudinal cohort study of adolescents, and 
then adults with multiple data points through a time series. 
This will allow testing many current hypotheses on the 
causal role of different major risk factors – social, environ-
mental, behavioural and genetic – in human disease and 
provide answers relevant to all human populations, rather 
than being limited to high-income countries. It would cre-
ate a reliable information base that could assist in under-
standing the burden of health problems in mothers and 
children globally. There would also be a role for this re-
source to help understand the genetic and other factors that 
make children prone to poor response or adverse effects of 
medicines or vaccines. The conduct of this coordinated 
study in a consistent way across many sites from low- and 
middle-income countries, starting with several ‘core’ sites 
and expanding through addition of other sites interested in 
following the same methodological approach, and includ-
ing up to 1 million newborns, would maximise the power 
to address many high priority research and health care sys-
tem questions. Results would also be generalisable globally, 
rather than confined to specific ethnic, social or economic 
groups. Through parallel recruitment and involvement of 
mothers, it would serve to integrate research into inter-
linked maternal and child health problems.
Building up an all-inclusive international biobank based 
on best research practice would, over time, develop into a 
resource that could serve the research needs of many di-
verse groups of researchers from developed and developing 
countries alike. The principle that would underlie this co-
hort is adherence to the highest ethical standards, which 
have now been developed through the setting up of large 
biobanks in developed countries, and also the principles 
of open access to anonymised data (consistent with adher-
ence to ethical principles and local approvals) to interested 
researchers with legitimate research ideas. This is in line 
with the emerging ‘open science’ framework, which en-
abled open discussion and reanalysis of existing data. Strin-
gent adherence to the highest ethical standards needs to be 
emphasized throughout each study as one of the goals of 
the larger project. The development of an international bio-
bank would involve the human and technological capacity 
of developing countries to work on this project and to as-
sist in building their research capacity and competitiveness.
In many countries there will be a strong sensitivity towards 
allowing foreign institutions to access genetic material. 
Most poor countries will rightly fear that any commercial 
interests from this type of research will only benefit rich 
countries. Some of them already have laws in place which 
restrict sending any biological materials outside their bor-
ders, particularly those that may have commercial implica-
tions. This is why planning an international birth cohort 
based on DNA will require developing of local capacity. Lo-
cal researchers will need to be trained to obtain biological 
materials in the same way across many field sites, store 
them properly, and generate data locally, while the analysis 
of the data could then be standardized and centralized. Pre-
Photo: Courtesy of Dr Martin Willi Weber, personal collection
V
IE
W
PO
IN
TS
	 www.jogh.org					June, 2011 • Vol. 1 No. 1       43
serving commercial interests from any patents and sharing 
them fairly with all the participants from low and middle 
income countries will represent an important challenge.
WHy IS THE TImE rIgHT?
We need a vision beyond the MDG4 timeframe of 2015. It 
is time to move beyond focusing on simply averting child 
deaths and to start planning for this resource. We now have 
standard operating procedures developed specifically for 
setting up biobanks and validated genetic technologies and 
analytical methods for replicable and reliable genetic anal-
yses (11,12). We also have standard ethics principles that 
are applicable to biobanks and large experience in setting 
up biobanks in high-income countries (13). Greatly im-
proved communication globally, through internet and mo-
bile phones, and cheaper international travel, has enabled 
a new kind of research. It is based on massive collabora-
tions of scientists, big projects and large sample sizes, and 
it generates more reliable results. We propose that global-
ization of the lifestyle, industry, and many other segments 
of human activity should be followed by globalization of 
research into human health and development. There is in-
creasingly a technological capacity in developing countries 
that could support this kind of vision. For example, sev-
eral large international organizations, multilateral agencies 
and even donor foundations have both the legitimacy and 
organisational infrastructure to provide parallel access to 
many field sites in low-income countries. They also repre-
sent a well-known ‘brands’ in the international communi-
ty that could ensure wide participation and commitment 
from all those taking part in this study. Some organizations 
and agencies maintain programmes of regular and repeated 
contacts with a high proportion of children in low resource 
settings, which could provide a highly cost-efficient frame-
work for recruitment and longitudinal follow up through-
out early childhood.
In addition, the incredibly fast progress in development of 
supporting genetic research technologies, which led to 
many recent genetic breakthroughs through genome-wide 
association studies, is beginning to make this vision in-
creasingly realistic. In fact, technological advances are now 
the main driver of the research progress. It can already be 
assumed that the appropriate research technologies will 
become affordable in several years to perform large-scale 
whole-genome sequencing projects. The costs of genotyp-
ing and sequencing of the human genome have been fall-
ing rapidly since the year 2000 – from about US$ 3 billion 
(€ 2.1 billion), which was spent to sequence the first hu-
man genome, to only about US$ 4000 (€ 2800) in early 
2011 (14–15). The time required to sequence the entire 
human genome has also fallen from 11 years to only a few 
hours (14–15).
We need to anticipate the possibility of affordable mass-
sequencing several years from now. With this vision, the 
remaining time would be well spent developing and as-
sembling the datasets from many countries and designing 
studies which will be the most informative, assuming the 
availability of genomic information (16).
WHaT SHOuld bE THE STudy dESIgN 
Of gENEraTION 2015?
The study sample should be large and represent many of 
the world’s populations. In each country, a local academic 
expert in paediatrics/neonatology or obstetrics would be 
identified and would be responsible for obtaining ethics 
approval from the nationally relevant body to conduct the 
study. This person should also be a key / committed mem-
ber of the study team and should own and drive the pro-
cess at the country level. 
The study would typically involve one large urban teach-
ing hospital and 3–4 health facilities in less developed and 
rural regions. In each country, a proportional number of 
newborns and mothers would be recruited to achieve a 
global sample size of up to 1 million newborns and as many 
of their mothers and fathers. A sample size of this magni-
tude is required to ensure sufficient number of cases with 
different social, economic, behavioural, health and devel-
opment outcomes in different contexts for an adequate, 
globally representative study. Each pregnant woman would 
be informed about the goals of the study and she would be 
asked to give informed consent for herself and the new-
born. In some countries, the signature of the father will also 
be required. At birth, a baseline questionnaire with the ba-
sic information would be filled out for each mother and 
child, and a blood sample would be obtained from each 
participant. Any complications during birth would be re-
corded, as well as the basic anthropometric, clinical and 
psychomotor assessment of the child.
rESEarcH OuTcOmES aNd bENEfITS 
Of gENEraTION 2015
Likely short term research outcomes of Generation 2015 for 
children would be: 
•  Description of the morbidity and mortality associ-
ated with major child diseases, preterm birth and 
pregnancy complications;
•  Description of normal and abnormal growth and 
development; and of health and disease from foetal 
life until early adulthood;
•  Identification of biological, environmental, genetic, 
and social risk factors and their interactions for 
major child diseases and pregnancy complications 
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in different contexts (including those associated 
with low birth weight, preterm birth and congeni-
tal anomalies; eclampsia, antepartum haemor-
rhage, placental abruption, thromboembolism and 
postpartum sepsis);
•  Identification of biological, environmental, genetic, 
and social determinants of host resistance against 
the major neonatal and childhood infections (such 
as neonatal sepsis, pneumonia, diarrhoea) and de-
terminants of immune system development;
•  Identification of biological, environmental, genetic, 
and social determinants of malnutrition and stunt-
ing (including micronutrient deficiencies);
•  Identification of biological, environmental, genetic, 
and social determinants of child development (in-
cluding motor, behavioural, cognitive and psycho-
motor development);
•  Understanding of genetic and environmental deter-
minants of host-pathogen interactions, carriage of 
microorganisms, immune response to vaccination, 
and antibiotic resistance.
•  Linking the whole genome studies to similar studies 
that are starting on global pathogens (17).
For mothers, short term research outcome could include: 
•  Description of the mortality and morbidity associ-
ated with the major maternal diseases and pregnan-
cy complications;
•  Identification of biological, environmental, genetic, 
and social risk factors for these conditions and their 
complications (including eclampsia, placenta pre-
via, lactation duration, postpartum haemorrhage, 
twinning, obstructed delivery, and puerperal sepsis) 
in different contexts.
Research outcome for participating countries could be:
•  Training of local staff and development of local re-
search capacity, establishing local biobanks and in-
ternational competitiveness in biobanking;
•  Possibility to participate in research at a high inter-
national level through large collaborations and to 
compare its capacity and progress in maternal and 
child health research with other countries.
Finally, likely indirect research opportunities afforded by 
Generation 2015 would be:
•  Identification of genes, gene-environment and gene-
social interactions;
•  Identification of biomarkers for birth related and 
early childhood disease outcomes or adverse events;
•  Establishing global standards for the frequency of 
gene variants in different populations;
•  Defining the content of a genotyping array contain-
ing the major disease associated variants across all 
global population groups;
•  Studying the effects of urbanization on genetic struc-
ture of populations and impact of admixture on dis-
ease traits;
•  Studying of the migrations of historical human pop-
ulations;
•  Looking for ‘signatures’ of natural selection in the 
genome.
WHaT IS THE PrOPOSEd STraTEgy Of 
dEVElOPmENT Of gENEraTION 2015?
In the first phase, several ‘core sites’ would be chosen in 
low- and middle-income countries, in which the approach 
would be piloted. The sites would fall in one of two catego-
ries: 1) they would be set up in each one of the BRICS 
countries – Brazil, Russia, India, China and South Africa – 
i.e., the five very large and rapidly developing economies. 
Those five countries are front-runners among the develop-
ing nations and their economic potential and research ca-
pacity are both on a remarkable increase. These countries 
should have most interest in, and ability to, harbour study 
sites in which DNA-based birth cohorts could be devel-
oped, as a logical next step necessary to acquire competi-
tiveness in genomic research at an international level; 2) 
they would be set up in several rare sites in low-income 
countries in which high-quality research was being con-
ducted for many years, and study populations are used to 
research of effectiveness of different interventions. These 
study sites were set up by driven individuals from low-in-
come countries, frequently through bilateral collaboration 
with a western institution. Because of randomized con-
trolled trials that are being conducted at such sites, the 
studies have availability of ‘cold chains’ required for vac-
cine delivery, appropriate ethics approvals, and a motivated 
team of researchers and study populations. They represent 
rare and relatively unique sites where a proper DNA-based 
biobank could be set up.
The pilot studies in those several selected sites would im-
prove our knowledge and understanding of the challenges 
with developing biobanks in low- and middle-income 
countries. We would aim to develop standardized study 
protocols based on those early experiences, and then invite 
groups from many more low- and middle-income countries 
to join this Generation 2015 with their data collections as-
sembled in a standardized way. Through this ‘snowballing’ 
development, we would hope to achieve sufficiently large 
numbers to develop a true international DNA-based birth 
cohort, which would allow studying of genetic determi-
nants of health and disease in children across the world, 
but also try to document the effects of inequity and socio-
economic differences on children’s biology and develop-
ment potential.
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